Nonsteroidal anti-inflammatory drugs: Cyclooxygenase 2 inhibitors

Jornal de Pediatria

Volumn 82, Issue SUPPL. 2, 2006, Pages

  Hilário, Maria Odete Esteves ^a,b   Terreri, Maria Teresa ^a   Len, Cláudio Arnaldo ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIFESP EPM ^*  (Brazil)

Author keywords

Adverse effects; COX 2 inhibitors; Indications; Nonsteroidal anti inflammatories

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; METHOTREXATE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARECOXIB; PHENYTOIN; PIROXICAM; ROFECOXIB; SULFONYLUREA DERIVATIVE; TOLMETIN; VALDECOXIB;

ACUTE HEART INFARCTION; ALLERGY; ANGIONEUROTIC EDEMA; APLASIA; ASTHMA; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHOLESTASIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DUODENITIS; DUODENUM ULCER; ERYTHEMA MULTIFORME; ESOPHAGITIS; FEVER; GASTRIC INTOLERANCE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL PAIN; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LIVER NECROSIS; LIVER TOXICITY; MEDULLA APLASIA; NAUSEA; NEUTROPENIA; PAIN; PEDIATRICS; PHOTOSENSITIVITY; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SKIN TINGLING; STEVENS JOHNSON SYNDROME; STOMACH IRRITATION; STOMACH ULCER; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

ADOLESCENT; ASPIRIN; CHILD; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; FEVER; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFLAMMATION; LEUKOTRIENES; NAPROXEN; PAIN; PROSTAGLANDINS; PYRAZOLES; PYRIDINES; SULFONAMIDES; SULFONES; THIAZINES; THIAZOLES; TREATMENT OUTCOME;

EID: 33845774442     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1560     Document Type: Review

References (28)

1. Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. Paediatr Drugs. 2001;3:817-58.
2. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol. 2004;33:1-6.
3. Cronstein BN. Cyclooxygenase-2 selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med. 2002;69:SI13-9.
4. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-42.
5. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, et al. Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002;99:13926-31.
6. Carvalho WA, Carvalho RD, Rios-Santos F. Specific cyclooxygenase -2 inhibitor analgesics: therapeutic advances. Rev Bras Anestesiol. 2004;54:448-64.
7. Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on Cox-2 versus Cox-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109-20.
8. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995;44:1-10.
9. Stempak D, Gammon J, Klein J, Koren G, Baruchel S. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther. 2002;72:490-7.
10. Burgos-Vargas R, Foeldvari I, Thon A, Linke R, Tuerck D. Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2004;44:866-72.
11. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med. 2004;158:521-6.
12. Bricks LF, Silva CAA. Recomendações para o uso de antiinflamatórios não hormonais em pediatria. Pediatria (São Paulo). 2005;27:114-25.
13. Anthony KK, Schanberg LE. Pediatric pain syndromes and management of pain in children and adolescents with rheumatic disease. Pediatr Clin North Am. 2005;52:611-39.
14. Ruperto N, Nikishina I, Pachanov ED, Shachbazian Y, Prieur AM, Mouy R, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52:563-72.
15. Reiff A, Lovell DJ, Adelsberg JV, Kiss MH, Goodman S, Zavaler MF, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006;33:98595.
16. Hochberg MC. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin Arthritis Rheum. 2002;32:4-14.
17. Weckx LL, Ruiz JE, Duperly J, Mendizabal GA, Rausis MB, Piltcher SL, et al. Efficacy of celecoxib in treating symptoms of viral pharyngitis: a double-blind, randomized study of celecoxib versus diclofenac. J Int Med Res. 2002;30:185-94.
18. Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodrigues R, Alfaya T. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients. J Investig Allergol Clin Immunol. 2003;13:20-5.
19. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. J Asthma. 2004;41:67-75.
20. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol. 2005;95:154-8.
21. Boehncke WH, Ludwig RJ, Zollner TM, Ochsendorf F, Kaufmann R, Gibbs BF. The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria. Br J Dermatol. 2003;148:604-6.
22. Len C, Hilario MO, Kawakami E, Terreri MT, Becker DJ, Goldenberg J, et al. Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology. 1999;46:991-6.
23. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum. 2005;53:185-97.
24. Ardoin SP, Sundy JS. Update on nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 2006;18:221-6.
25. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk - where are we now? Nat Clin Pract Cardiovasc Med. 2005;2:290-300.
26. Melnikova I. Future of cox2 inhibitors. Nat Rev Drug Discov. 2005;4:453-4.
27. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27:1657-63.
28. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ. 2006;332:1302-9.